Yan, Chenglan
46  Ergebnisse:
Personensuche X
?
1

Long-Term Efficacy and Low Adverse Events of Methylpredniso..:

Cheng, Hao ; Yu, Zhen ; Yan, Cheng-lan...
Journal of Inflammation Research.  15 (2022)  - p. 4421-4433 , 2022
 
?
3

Absolute decrease in regulatory T cells and low-dose interl..:

Yu, Zhen ; Cheng, Hao ; Ding, Tingting...
Clinical and Experimental Dermatology.  47 (2022)  12 - p. 2188-2195 , 2022
 
?
5

Decreased numbers and sex-based differences of circulating ..:

Niu, Hong-Qing ; Yuan, Chenrui ; Yan, Chenglan...
Therapeutic Advances in Chronic Disease.  12 (2021)  - p. 204062232098672 , 2021
 
?
6

Efficacy of Belimumab for refractory systemic lupus erythem..:

Cheng, Hao ; Zhao, Chen-sheng ; Yan, Cheng-lan..
European Journal of Internal Medicine.  92 (2021)  - p. 117-120 , 2021
 
?
8

Long-Term Efficacy and Low Adverse Events of Methylpredniso..:

Cheng, Hao ; Yu, Zhen ; Yan, Cheng-lan...
info:eu-repo/semantics/altIdentifier/doi/10.2147/JIR.S373387.  , 2022
 
?
 
?
10

Long-Term Efficacy and Low Adverse Events of Methylpredniso..:

Cheng, Hao ; Yu, Zhen ; Yan, Cheng-lan...
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9359792/.  , 2022
 
?
11

Decreased Absolute Number of Circulating Regulatory T Cells..:

Jia, Wen ; Fu, Zi-Li ; Wang, Xia...
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8732761/.  , 2021
 
?
 
?
13

Decreased Serum 25-(OH)-D Level Associated With Muscle Enzy..:

Yu, Zhen ; Cheng, Hao ; Liang, Yuying...
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8082096/.  , 2021
 
1-15